|
|
Plantacor, Inc. is a specialty biopharmaceutical company engaged in the development of therapeutic drugs for the treatment of cancer and other human diseases. The Company’s strategy is to fill the developmental gap between basic institutional research and clinical development. This will be accomplished for lead drug candidates by addressing manufacturing challenges, designing an appropriate drug delivery system, completing preclinical work, filing Investigational New Drug (IND) applications and entering human clinical trials.
The Company’s first product candidates are focused on unique analogs and novel formulations of known tumor growth inhibiting compounds derived from natural sources. According to the National Cancer Institute, approximately 70% of the currently approved anticancer drugs are either natural compounds, derived therefrom, or mimic natural compounds in one form or another - a proven resource for oncology drugs. Clearly, starting with recognized effective natural compounds, modifying them by chemical structure or formulation for delivery, while improving efficacy and maintaining the safety profile of the original compound, is a successful formula for rapid advancement of drug candidates to human clinical trials for use as therapeutic drugs for the treatment of various types of cancer.
|  Initial Target Breast cancer is the most common cancer in women and affects one in eight during their lifetime. Breast cancer kills more women in the United States than any other cancer except lung cancer. In 2005 basal-like or "triple negative" breast cancer was identified and characterized. Basal-like breast cancer has some unique characteristics and is the type of breast cancer that BRCA1 mutation (genetic marker) carriers generally develop. It comprises about 15% of all breast cancers, but represents 39% of young African-American women who develop breast cancer. It is very aggresive and has a high mortality rate. It is primarily treated with chemotherapy and is not a candidate for ER-targeted or HER2-targeted therapies. It is the target of our first drug candidate, CDIM9.
Status We are currently completing the preclinical evaluations, preparing the Investigational New Drug (IND) application and anticipate entering human clinical trials in 2009. | Plantacor, Inc. 526 University Dr. East Suite 101A College Station, TX 77840 Tel: 979.694.8205 Fax: 979.693.0811 |
|
|